Tags

Type your tag names separated by a space and hit enter

Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
Clin Cancer Res. 2001 Dec; 7(12):4073-9.CC

Abstract

PURPOSE

To analyze the possible correlation between expression of the alphav and beta1 integrin chains and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome.

EXPERIMENTAL DESIGN

Sections from 56 primary ovarian carcinomas and metastatic lesions from 34 patients diagnosed with advanced-stage ovarian carcinoma (Fédération Internationale des Gynaecologistes et Obstetristes stages III-IV), divided into long-term (16) and short-term (18) survivors, were evaluated for expression of alphav and beta1 integrin chains using mRNA in situ hybridization. Protein expression was additionally studied in 52 specimens using immunohistochemistry.

RESULTS

The mean values for disease-free survival and overall survival were 115 and 132 months for long-term survivors, as compared with 4 and 23 months for short-term survivors, respectively. Expression of alphav integrin mRNA was observed in carcinoma (18 of 56; 32%) and stromal (17 of 56; 30%) cells. beta1 integrin mRNA was similarly detected in carcinoma (25 of 56; 47%) and stromal (19 of 56; 34%) cells. No significant differences were observed when primary and metastatic lesions were compared (P > 0.05). Alphav integrin mRNA was present more often in carcinoma cells in tumors of short-term survivors (P = 0.017 for carcinoma cells). In univariate survival analysis for all cases, alphav integrin mRNA expression in tumor cells correlated with poor survival (P = 0.012). This finding retained its predictive power in a multivariate survival analysis, in which all of the molecules studied previously in this patient cohort were included (P = 0.031). Immunohistochemistry confirmed the differences in alphav integrin expression in tumor cells of short-term as compared with long-term survivors, whereas beta1 integrin protein expression was comparable in the two groups.

CONCLUSIONS

To our best knowledge, this is the first evidence associating integrin expression with poor survival in ovarian carcinoma. Alphav integrin is, thus, a novel prognostic marker in advanced-stage ovarian carcinoma.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Goldberg I
Department of Pathology, Sheba Medical Center, Tel-Hashomer 52621, Israel.
Davidson B
No affiliation info available
Reich R
No affiliation info available
Gotlieb WH
No affiliation info available
Ben-Baruch G
No affiliation info available
Bryne M
No affiliation info available
Berner A
No affiliation info available
Nesland JM
No affiliation info available
Kopolovic J
No affiliation info available

MeSH

AdultAgedAged, 80 and overAntigens, CDDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansIntegrin alphaVIntegrin beta1Middle AgedNeoplasm StagingOvarian NeoplasmsPrognosisRNA, MessengerStromal CellsSurvival RateTime FactorsTranscription, Genetic

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11751504

Citation

Goldberg, I, et al. "Alphav Integrin Expression Is a Novel Marker of Poor Prognosis in Advanced-stage Ovarian Carcinoma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 7, no. 12, 2001, pp. 4073-9.
Goldberg I, Davidson B, Reich R, et al. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res. 2001;7(12):4073-9.
Goldberg, I., Davidson, B., Reich, R., Gotlieb, W. H., Ben-Baruch, G., Bryne, M., Berner, A., Nesland, J. M., & Kopolovic, J. (2001). Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 7(12), 4073-9.
Goldberg I, et al. Alphav Integrin Expression Is a Novel Marker of Poor Prognosis in Advanced-stage Ovarian Carcinoma. Clin Cancer Res. 2001;7(12):4073-9. PubMed PMID: 11751504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. AU - Goldberg,I, AU - Davidson,B, AU - Reich,R, AU - Gotlieb,W H, AU - Ben-Baruch,G, AU - Bryne,M, AU - Berner,A, AU - Nesland,J M, AU - Kopolovic,J, PY - 2001/12/26/pubmed PY - 2002/3/28/medline PY - 2001/12/26/entrez SP - 4073 EP - 9 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 7 IS - 12 N2 - PURPOSE: To analyze the possible correlation between expression of the alphav and beta1 integrin chains and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome. EXPERIMENTAL DESIGN: Sections from 56 primary ovarian carcinomas and metastatic lesions from 34 patients diagnosed with advanced-stage ovarian carcinoma (Fédération Internationale des Gynaecologistes et Obstetristes stages III-IV), divided into long-term (16) and short-term (18) survivors, were evaluated for expression of alphav and beta1 integrin chains using mRNA in situ hybridization. Protein expression was additionally studied in 52 specimens using immunohistochemistry. RESULTS: The mean values for disease-free survival and overall survival were 115 and 132 months for long-term survivors, as compared with 4 and 23 months for short-term survivors, respectively. Expression of alphav integrin mRNA was observed in carcinoma (18 of 56; 32%) and stromal (17 of 56; 30%) cells. beta1 integrin mRNA was similarly detected in carcinoma (25 of 56; 47%) and stromal (19 of 56; 34%) cells. No significant differences were observed when primary and metastatic lesions were compared (P > 0.05). Alphav integrin mRNA was present more often in carcinoma cells in tumors of short-term survivors (P = 0.017 for carcinoma cells). In univariate survival analysis for all cases, alphav integrin mRNA expression in tumor cells correlated with poor survival (P = 0.012). This finding retained its predictive power in a multivariate survival analysis, in which all of the molecules studied previously in this patient cohort were included (P = 0.031). Immunohistochemistry confirmed the differences in alphav integrin expression in tumor cells of short-term as compared with long-term survivors, whereas beta1 integrin protein expression was comparable in the two groups. CONCLUSIONS: To our best knowledge, this is the first evidence associating integrin expression with poor survival in ovarian carcinoma. Alphav integrin is, thus, a novel prognostic marker in advanced-stage ovarian carcinoma. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/11751504/Alphav_integrin_expression_is_a_novel_marker_of_poor_prognosis_in_advanced_stage_ovarian_carcinoma_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=11751504 DB - PRIME DP - Unbound Medicine ER -